MedPath

se of Urinary Neutrophil Gelatinase Associated Lipocalin (uNGAL) in predicting spontaneous bacterial peritonitis in cirrhosis.

Not Applicable
Conditions
Health Condition 1: K703- Alcoholic cirrhosis of liverHealth Condition 2: K721- Chronic hepatic failureHealth Condition 3: K652- Spontaneous bacterial peritonitis
Registration Number
CTRI/2021/09/036783
Lead Sponsor
Taurus Life Sciences Company
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Diagnosed cases of decompensated cirrhosis of liver with ascites, with a diagnostic paracentesis done at current admission.

Exclusion Criteria

Pre-existing renal disease/CKD, AKI at the time of hospitalization, renal replacement therapy, secondary peritonitis, malignant diseases, prior antibiotic therapy, urinary tract infection

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Presence of spontaneous bacterial peritonitis and prognosisTimepoint: At time of recruitment and at the end of 30 days (day 0 and day 30)
Secondary Outcome Measures
NameTimeMethod
Comparision of urinary NGAL level with renal dysfunctionTimepoint: Day 0;To co-relate uNGAL levels with other ascitic parametersTimepoint: Day 0;TO compare uNGAL and survivalTimepoint: Day 30;To compare uNGAL in SBP and non-SBP groupTimepoint: Day 0
© Copyright 2025. All Rights Reserved by MedPath